Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eziopitant. Pfizer.

S Evangelista1

  • 1Menarini Ricerche SpA, Sette Santi, Florence, Italy. sevangelista@menarini-ricerche.it

Current Opinion in Investigational Drugs (London, England : 2000)
|March 14, 2002
PubMed
Summary
This summary is machine-generated.

Ezlopitant, a neurokinin-1 antagonist, showed promise for irritable bowel syndrome (IBS) after its development for chemotherapy-induced emesis was discontinued. Further research is needed to confirm its efficacy in IBS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Prototype E-Textile Sock.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2020
Same author

Changes of excitatory and inhibitory neurotransmitters in the colon of rats underwent to the wrap partial restraint stress.

Neurogastroenterology and motility·2016
Same author

Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Neurogastroenterology and motility·2015
Same author

Chronic treatment with otilonium bromide induces changes in L-type Ca²⁺ channel, tachykinins, and nitric oxide synthase expression in rat colon muscle coat.

Neurogastroenterology and motility·2013
Same author

Comparison between the effects of lisinopril and losartan on the cougn reflex in anesthetized and awake rabbits.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2013
Same author

Effect of otilonium bromide and ibodutant on the internalization of the NK2 receptor in human colon.

Neurogastroenterology and motility·2010
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Pharmacology
  • Gastroenterology

Background:

  • Ezlopitant is a neurokinin-1 antagonist developed by Pfizer.
  • Previous trials investigated ezlopitant for chemotherapy-induced emesis and irritable bowel syndrome (IBS).

Purpose of the Study:

  • To assess the safety and efficacy of ezlopitant for controlling cisplatin-induced emesis.
  • To explore the potential of ezlopitant in treating irritable bowel syndrome (IBS).

Main Methods:

  • Phase II, double-blind, randomized study for emesis.
  • Pilot study involving 14 IBS patients.

Main Results:

  • Ezlopitant was well-tolerated in emesis trials.
  • The compound effectively controlled emesis but was less effective against nausea.

Related Experiment Videos

  • Development for emesis was discontinued due to limited efficacy in nausea control.

    • Conclusions:

    • Ezlopitant demonstrated safety and efficacy in controlling emesis.
    • Further investigation is warranted for ezlopitant's potential in IBS treatment.